Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
J Am Soc Nephrol. 2018 Feb;29(2):477-491. doi: 10.1681/ASN.2017040385. Epub 2017 Oct 23.
Progress in research and developing therapeutics to prevent diabetic kidney disease (DKD) is limited by a lack of animal models exhibiting progressive kidney disease. Chronic hypertension, a driving factor of disease progression in human patients, is lacking in most available models of diabetes. We hypothesized that superimposition of hypertension on diabetic mouse models would accelerate DKD. To test this possibility, we induced persistent hypertension in three mouse models of type 1 diabetes and two models of type 2 diabetes by adeno-associated virus delivery of renin (ReninAAV). Compared with LacZAAV-treated counterparts, ReninAAV-treated type 1 diabetic Akita/129 mice exhibited a substantial increase in albumin-to-creatinine ratio (ACR) and serum creatinine level and more severe renal lesions. In type 2 models of diabetes (C57BKLS and BTBR mice), compared with LacZAAV, ReninAAV induced significant elevations in ACR and increased the incidence and severity of histopathologic findings, with increased serum creatinine detected only in the ReninAAV-treated mice. The uninephrectomized ReninAAV model was the most progressive model examined and further characterized. In this model, separate treatment of hyperglycemia with rosiglitazone or hypertension with lisinopril partially reduced ACR, consistent with independent contributions of these disorders to renal disease. Microarray analysis and comparison with human DKD showed common pathways affected in human disease and this model. These results identify novel models of progressive DKD that provide researchers with a facile and reliable method to study disease pathogenesis and support the development of therapeutics.
研究和开发预防糖尿病肾病 (DKD) 的治疗方法的进展受到缺乏表现出进行性肾病的动物模型的限制。在大多数可用的糖尿病模型中,慢性高血压是人类患者疾病进展的驱动因素,但在这些模型中并不存在。我们假设将高血压叠加在糖尿病小鼠模型上将加速 DKD 的进展。为了验证这一可能性,我们通过腺相关病毒 (AAV) 传递肾素 (ReninAAV),在三种 1 型糖尿病小鼠模型和两种 2 型糖尿病模型中诱导持续性高血压。与 LacZAAV 处理的对照相比,ReninAAV 处理的 1 型糖尿病 Akita/129 小鼠的白蛋白与肌酐比 (ACR) 和血清肌酐水平显著增加,肾脏病变更严重。在 2 型糖尿病模型(C57BKLS 和 BTBR 小鼠)中,与 LacZAAV 相比,ReninAAV 诱导 ACR 显著升高,并增加了组织病理学发现的发生率和严重程度,仅在 ReninAAV 处理的小鼠中检测到血清肌酐升高。未进行单侧肾切除术的 ReninAAV 模型是检查和进一步表征的最具进展性模型。在该模型中,用罗格列酮单独治疗高血糖或用赖诺普利单独治疗高血压部分降低了 ACR,这与这些疾病对肾脏疾病的独立贡献一致。微阵列分析并与人类 DKD 进行比较显示,在人类疾病和该模型中存在共同受影响的途径。这些结果确定了新型进行性 DKD 模型,为研究人员提供了一种简便可靠的方法来研究疾病发病机制,并支持治疗方法的开发。